Premium
The metabolic syndrome in overweight epileptic patients treated with valproic acid
Author(s) -
Verrotti Alberto,
Manco Rossella,
Agostinelli Sergio,
Coppola Giangennaro,
Chiarelli Francesco
Publication year - 2010
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1167.2009.02206.x
Subject(s) - medicine , dyslipidemia , valproic acid , abdominal obesity , overweight , metabolic syndrome , endocrinology , obesity , triglyceride , gastroenterology , epilepsy , cholesterol , psychiatry
Summary Purpose: To evaluate the presence of metabolic syndrome (MS) in children and adolescents treated with valproate (VPA). Methods: One hundred fourteen patients (54 male and 60 female) were studied. These patients were followed from the beginning of therapy for at least 24 months; at the end of follow‐up, 46 patients (40.4%) had a considerable increase in body weight, whereas the other patients (59.6%) remained with the same weight. The MS was defined as having at least three of the following: abdominal obesity, dyslipidemia, glucose intolerance, and hypertension. Results: Forty‐six patients developed obesity; 20 (43.5%) of 46 patients developed MS. Abnormal glucose homeostasis was identified in 45% of patients. High total serum cholesterol concentrations were noted in 10 (50%), high serum triglyceride concentrations in 7 (35%), and low high‐density lipoprotein (HDL) in 15 (75%) of the 20 subjects with MS. However, there were no significant differences in the features of MS between boys and girls with MS. Conclusions: Patients who gain weight during VPA therapy can develop MS with a possible risk of cardiovascular disease.